<DOC>
	<DOCNO>NCT00038493</DOCNO>
	<brief_summary>This study combine chemotherapy agent temozolomide investigational drug SCH66336 ( agent interfere new cell growth ) . Patients treat oral temozolomide day 1-5 oral SCH66336 day 8-28 every 28 day .</brief_summary>
	<brief_title>Temozolomide SCH66336 Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description>Temozolomide dose , 150-200 mg/m2 , administer orally , fast one hour , day 5 consecutive day ( day 1 5 ) every 4 week ( plus 3 day ) . The start dose level 200 mg/m2 use patient previously receive chemotherapy 150 mg/m2 patient receive previous chemotherapy . SCH66336 give orally , water , morning evening three week ( Days 8 - 28 ) every 28 day ( plus 3 day ) 1 hour morning evening meal . Patients take 150 mg morning 150 mg evening . Treatment course may repeat every 28 day follow first daily dose Temozolomide previous course .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Inclusion : Patients histologically prove supratentorial glioblastoma multiforme ( GBM ) . Patients must show unequivocal evidence tumor recurrence progression MRI scan radiation therapy . The scan do prior study entry document progression review primary investigator document tumor volume change provide gross assessment growth rate . Patients may : ) prior chemotherapy , b ) 1 prior adjuvant chemotherapy , c ) 1 prior adjuvant chemotherapy follow 1 regimen recurrent disease , ) 1 2 prior chemotherapy regimens recurrent progressive tumor . All patient must sign informed consent indicate aware investigational nature study keep policy hospital . Patients must show unequivocal evidence tumor progression MRI CT scan . A scan performed within 14 day prior registration steroid dose stable least 5 day . If steroid dose increase date image registration new baseline MR/CT require . The type scan , i.e. , MRI CT must use throughout period protocol treatment tumor measurement . Patients undergone recent resection recurrent progressive tumor eligible long follow condition apply : 1 . They recover effect surgery . 2 . Residual disease follow resection recurrent tumor mandate eligibility study . To best assess extent residual disease postoperatively , CT/ MRI do later 96 hour immediate postoperative period least 4 week postoperatively , within 14 day prior registration . If 96hour scan 14 day registration , scan need repeat . If steroid dose increase date imaging registration , new baseline MRI/CT require stable steroid dosage least 5 day . Patients must &gt; 18 year old , life expectancy &gt; 8 week . Patients must Karnofsky performance status &gt; 60 ( Karnofsky Performance Scale ; Appendix C ) . Patients must recover toxic effect prior therapy : 4 week prior cytotoxic therapy and/or least two week vincristine , 6 week nitrosoureas , 3 week procarbazine administration , 1 week noncytotoxic agent , e.g. , interferon , tamoxifen , thalidomide , cisretinoic acid , etc . ( radiosensitizer count ) . Any question relate definition noncytotoxic agent direct Study Chair . Patients must adequate bone marrow function ( ANC &gt; 1,500/mm3 platelet count &gt; 100,000/mm3 ) , adequate liver function ( SGPT alkaline phosphatase &lt; 2 time normal , bilirubin &lt; 1.5 mg % ) , adequate renal function ( BUN creatinine &lt; 1.5 time institutional normal ) prior start therapy . Patients must normal QT interval EKG do within 2 week prior study entry . Patients must take primidone , carbamazepine , phenobarbital phenytoin anticonvulsant . Patients change anticonvulsant others allow must drug list least 72 hour . Patients history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) , unless complete remission therapy disease minimum 3 year ineligible . Patients must : 1. active infection 2. disease obscure toxicity dangerously alter drug metabolism 3. serious intercurrent medical illness . 4. prior recurrence either Temozolomide farnesyl transferase inhibitor 5. oral contraceptive hormonal method ( DepoProvera ) birth control . Patients must pregnant male female patient must practice adequate contraception . Exclusion : Patients history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) , unless complete remission therapy disease minimum 3 year ineligible . Patients follow ineligible : 1. active infection 2. pregnancy must practice adequate contraception 3. disease obscure toxicity dangerously alter drug metabolism 4. serious intercurrent medical illness 5. previous treatment either Temozolomide farnesyl transferase inhibitor 6. oral contraceptive hormonal method ( DepoProvera ) birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>GBM</keyword>
	<keyword>Glioma</keyword>
	<keyword>Brain Tumor</keyword>
</DOC>